New tablet form aims to protect kidneys in transplant patients
NCT ID NCT07267208
Summary
This study is testing if switching stable liver transplant patients from their regular entecavir pill to a new dissolving tablet version is safe and effective. The main goal is to see if the new tablet helps protect the patients' kidney function over 48 weeks. Researchers will also check if the virus stays controlled and if the easier-to-take tablet improves how consistently patients take their medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.